DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
OCE Oncology Regulatory Affairs and Policy Program
Abstract. MYC is an oncogenic transcription factor that binds gene promoters to facilitate oncogenic gene expression. When overexpressed, as is the case in most human…
TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
An abstract is unavailable.
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.
By Denny Dyroff, Entertainment Editor, The Times A pentagon has five sides and a hexagon has six sides. A heptagon has seven sides. An octagon…